Coexistence, North American style: regulation and litigation.

Globally, biotech crops have left a legacy of success and some notable failures due to regulatory and litigious barriers to entry, with a pipeline of potentially beneficial biotech agricultural products lined up and awaiting approval. Compared with traditional agriculture, these crops provide significant health benefits to environmental and human health benefits, including organic systems. While the rest of the world has increased acreage of biotech crops at a steady annual rate of 10%, North America-the birthplace of most biotech crops-has reached a critical turning point in its regulatory evolution. Biotech crops can play a major role in creating a more sustainable agricultural landscape, which is increasingly well-documented, but future commercial use may be hampered by regulation and litigation that place organic and non-GMO agriculture on a pedestal, which could force many biotech crops into containment. If producers of biotech crops are required to prevent their crops from contaminating these other, high premium specialty crops through migration, innovation in agricultural biotechnology will suffer (as the European experience with agricultural biotechnology clearly demonstrates).